Phosphate binders are among the most common medications prescribed to patients with
kidney failure receiving dialysis and are often used in advanced chronic kidney disease …

Introduction Hyperphosphatemia is an inevitable complication for patients undergoing
dialysis, as is the resulting need for treatment with phosphate binders. Currently, various …

Introduction Among the clinical and metabolic complications of progressive chronic kidney
disease (CKD), CKD-mineral bone disorder (CKD-MBD) significantly contributes to morbidity …

Disturbances of mineral metabolism occur during the early stages of chronic kidney disease.
As renal function worsens, excess dietary phosphorus accumulates and blood levels …

Introduction: Hyperphosphatemia in chronic kidney disease (CKD) is considered as an
independent risk factor for surrogate clinical end points like vascular calcification (VC) and …

Phosphate levels are strikingly associated with poor outcomes in chronic kidney disease
(CKD) and endstage renal disease (ESRD) patients. Numerous epidemiological studies …

Adequate phosphate management in end-stage CKD remains a mainstay of our therapeutic
approaches in this population, and additional promising drugs are in development and may …

Bone disease and ectopic calcification are the two main consequences of
hyperphosphataemia of chronic kidney disease (CKD). Observational studies have …

The recent publication of the novel KDIGO™ chronic kidney disease (CKD) guidelines in
2009 [1] clearly underlined the importance of bone and vascular health for patients with …

Page 2 of 12 factors causes accelerated ageing and vascular calcification. These risk factors
push vascular smooth cells to transform into ostecondro-genic cells (12). With multiple …